SGLT2i or gliflozins were effective, albeit modest hypoglycemic agents when compared to other glucose-lowering drugs such as sulfonylureas or GLP-1 RA, but with substantial favorable CV/renal benefits, thus supporting their use beyond T2D [117]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.